West Branch Capital’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
Other funds holding AZN
IA
VCM
VAM
West Branch Capital's AZN Position: Q1 2026 in Review
West Branch Capital sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 50 shares — an estimated $9.19K sold.
West Branch Capital first reported a position in AZN in Q3 2024 and held it in 3 quarters. The position peaked at $9.19K in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- West Branch Capital reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
- West Branch Capital sold 50 AstraZeneca shares in Q1 2026, an estimated $9.19K.
- West Branch Capital first reported a position in AstraZeneca in Q3 2024 and held it in 3 quarters.
- West Branch Capital's AstraZeneca position peaked at $9.19K in Q4 2025.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on West Branch Capital's 13F filing for Q1 2026, filed 14 Apr 2026.